<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS98622</article-id>
<article-id pub-id-type="doi">10.1101/2020.10.16.342410</article-id>
<article-id pub-id-type="archive">PPR227166</article-id>
<article-version article-version-type="publisher-id">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Schloer</surname>
<given-names>Sebastian</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brunotte</surname>
<given-names>Linda</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mecate-Zambrano</surname>
<given-names>Angeles</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zheng</surname>
<given-names>Shuyu</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tang</surname>
<given-names>Jing</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ludwig</surname>
<given-names>Stephan</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rescher</surname>
<given-names>Ursula</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Institute of Medical Biochemistry, Center for Molecular Biology of Inflammation, and “Cells in Motion” Interfaculty Centre, University of Muenster, Von-Esmarch-Str. 56, D-48149, Muenster, Germany</aff>
<aff id="A2">
<label>2</label>Institute of Molecular Virology, Center for Molecular Biology of Inflammation, and “Cells in Motion” Interfaculty Centre, University of Muenster, Von-Esmarch-Str. 56, D-48149, Muenster, Germany</aff>
<aff id="A3">
<label>3</label>Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Haartmaninkatu 8, 00029, Helsinki, Finland</aff>
<author-notes>
<corresp id="CR1">
<label>*</label>Correspondence: Ursula Rescher, <email>rescher@uni-muenster.de</email>, Tel. +492518352118, Fax. +492518356748</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>18</day>
<month>10</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="preprint">
<day>16</day>
<month>10</month>
<year>2020</year>
</pub-date>
<permissions>
<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<p id="P1">The SARS-COV-2 pandemic and the global spread of coronavirus disease 2019 (COVID-19) urgently calls for efficient and safe antiviral treatment strategies. A straightforward approach to speed up drug development at lower costs is drug repurposing. Here we investigated the therapeutic potential of targeting the host-SARS-CoV-2 interface via repurposing of clinically licensed drugs and evaluated their use in combinatory treatments with virus- and host-directed drugs. We tested the antiviral potential of repurposing the antifungal itraconazole and the antidepressant fluoxetine on the production of infectious SARS-CoV-2 particles in the polarized Calu-3 cell culture model and evaluated the added benefit of a combinatory use of these host-directed drugs with remdesivir, an inhibitor of viral RNA polymerase. Drug treatments were well-tolerated and potent impaired viral replication was observed with all drug treatments. Importantly, both itraconazole-remdesivir and fluoxetine-remdesivir combinations inhibited the production of infectious SARS-CoV-2 particles &gt; 90% and displayed synergistic effects in commonly used reference models for drug interaction. Itraconazole-Remdesivir and Fluoxetine-Remdesivir combinations are promising therapeutic options to control SARS-CoV-2 infection and severe progression of COVID-19.</p>
</abstract>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p id="P2">The zoonotic coronavirus SARS-CoV-2 and the resulting COVID-19 pandemic impressively show the global threat potential of a newly emerging pathogen. More than one million people have died so far from the current outbreak, and the proportion of infected people was estimated to reach more than 10% of the global population, with still unknown fatality rates (<xref ref-type="bibr" rid="R4">Baud et al., 2020</xref>; <xref ref-type="bibr" rid="R27">Rajgor et al., 2020</xref>; <xref ref-type="bibr" rid="R39">Wu et al., 2020</xref>). Because of the pressing burden on national health systems and economic losses, safe and efficient treatment strategies are urgently required. Developing a vaccine is a high priority. However, the rigorous testing and extensive clinical trials are time-consuming processes. While several trials are already ongoing, there are no vaccines available yet, and the required widespread access remains a challenging future task. Thus, approaches other than immunization might offer useful additional options for the management and control of SARS-CoV-2 infection and the treatment of COVID-19 (<xref ref-type="bibr" rid="R8">Fierabracci et al., 2020</xref>). A possibility to speed up the availability of drugs for the treatment of novel infections is the use of drugs that are already in clinical use for unrelated diseases via so-called "drug repurposing". This approach represents a promising strategy to identify antiviral drugs with faster clinical implementation and lower development costs, considerations that are especially important in the global COVID-19 pandemic (<xref ref-type="bibr" rid="R26">Pushpakom et al., 2018</xref>). In addition to drugs that directly target the virus, host cell components that are vitally important in the viral life cycle are explored as promising starting points for therapeutic intervention (“host cell-directed therapy”) (<xref ref-type="bibr" rid="R31">Schwegmann and Brombacher, 2008</xref>; <xref ref-type="bibr" rid="R14">Ianevski et al., 2020</xref>; <xref ref-type="bibr" rid="R41">Zumla et al., 2020</xref>).</p>
<p id="P3">Although proteolytic cleavage of the SARS-CoV-2 spike protein surface protein by the host cell transmembrane protease serine 2 (TMPRSS2) enables SARS-CoV-2 to directly fuse with the plasma membrane, endocytosed SARS-CoV-2 particles use endosome-residing proteases for fusion within endosomes (<xref ref-type="bibr" rid="R36">Tang et al., 2020</xref>). Both pathways contribute to the SARS-CoV-2 infection process, and the preferential use of the actual fusion pathway might critically depend on the presence of plasma membrane proteases (<xref ref-type="bibr" rid="R12">Hoffmann et al., 2020</xref>). Our earlier research on influenza virus infection identified the late endosomal cholesterol balance as a critical factor in the influenza infection success and established this viral entry point as a possible pharmacological target. Elevated cholesterol levels inhibit the fusion of the influenza lipid hull with the endosomal membranes and thus inhibit the efficient transfer of the viral genome into the host cytosol (<xref ref-type="bibr" rid="R22">Musiol et al., 2013</xref>; <xref ref-type="bibr" rid="R17">Kühnl et al., 2018</xref>). We found that the clinically licensed antifungal itraconazole, a triazole derivative that blocks the fungal ergosterol pathway, has antiviral properties against a range of viruses and is effective against IAV infections in a preclinical mouse model (<xref ref-type="bibr" rid="R29">Schloer et al., 2019</xref>, <xref ref-type="bibr" rid="R30">2020b</xref>). The additional therapeutic function is most likely based on direct inhibition of the endosomal cholesterol transporter Niemann-Pick Type C1 (NPC1) and the subsequent cholesterol storage ((<xref ref-type="bibr" rid="R37">Trinh et al., 2017</xref>; <xref ref-type="bibr" rid="R29">Schloer et al., 2019</xref>)).</p>
<p id="P4">The late endosome is an entry site for many zoonotically transmitted viruses, in particular for enveloped viruses including SARS-CoV-2 (<xref ref-type="bibr" rid="R36">Tang et al., 2020</xref>). Because of the functional similarities in transmitting the viral genome into the host cell, the same endosomal components might serve as pharmacological targets for a broad host-directed antiviral strategy against such viruses. Continuing our work on the endosomal host-virus interface, we explored whether a similar repurposing strategy could be used to impair SARS-CoV-2 entry and infection. Therefore, we assessed clinically licensed drugs that also affect endolysosomal lipid storage and cholesterol build-up for their antiviral potential. Here we report that itraconazole treatment potently inhibited the production of SARS-CoV-2 infectious particles. Together with our recently published work on the antiviral potential of the widely used serotonin inhibitor fluoxetine, which also negatively affects endosomal cholesterol release (<xref ref-type="bibr" rid="R16">Kornhuber et al., 2010</xref>; <xref ref-type="bibr" rid="R28">Schloer et al., 2020a</xref>) on SARS-CoV-2 infection, the results presented in this study strongly argue for the endolysosomal host-SARs-CoV-2 interface as a druggable target. However, host-directed drugs will rather suppress infection than completely eradicate the pathogen. The resulting demand for high drug doses and early and prolonged treatment is often associated with poor patient compliance. While drugs directly acting on virus structures are much more likely to completely eliminate the pathogens in shorter treatment time, emerging viral resistance to these antivirals is a major concern, as observed with the influenza neuraminidase inhibitor oseltamivir (<xref ref-type="bibr" rid="R15">Kim et al., 2013</xref>). Thus, combination therapies using virus- and host-directed drugs are considered to overcome these shortcomings. The nucleoside analog remdesivir which was originally developed against Ebola (<xref ref-type="bibr" rid="R38">Warren et al., 2016</xref>), has antiviral properties with a broad spectrum of activity against a number of RNA viruses and has already been shown to be effective against SARS and Mers-CoV in animal experiments (<xref ref-type="bibr" rid="R32">Sheahan et al., 2017</xref>, <xref ref-type="bibr" rid="R33">2020</xref>; <xref ref-type="bibr" rid="R1">Agostini et al., 2018</xref>; <xref ref-type="bibr" rid="R25">Pruijssers et al., 2020</xref>). When remedesivir is incorporated into the viral RNA, the synthesis is prematurely terminated, and viral replication is inhibited (<xref ref-type="bibr" rid="R9">Gordon et al., 2020</xref>). Therefore, we explored combined treatments with remdesivir and the repurposed drugs itraconazole and fluoxetine. Both drug combinations showed stronger antiviral activities against influenza viruses compared to remdesivir monotherapy (<xref ref-type="bibr" rid="R30">Schloer et al., 2020b</xref>). Importantly, the antiviral effects of the combined treatments deviated from the expected effects, and pharmacodynamic evaluation via commonly used reference models to study drug interaction revealed synergistic interaction.</p>
</sec>
<sec id="S2" sec-type="materials | methods">
<label>2</label>
<title>Materials and Methods</title>
<sec id="S3">
<label>2.1</label>
<title>Cells and SARS-CoV-2 isolate</title>
<p id="P5">The human bronchial epithelial cell lines Calu-3 and the Vero E6 cells were cultivated in Dulbecco’s modified Eagle’s medium (DMEM) with 10% standardized fetal bovine serum (FBS Superior; Merck), 2 mM L-glutamine, 100 U/mL penicillin, 0.1 mg/mL streptomycin, and 1% non-essential amino acids (Merck) in a humidified incubator at 5% CO<sub>2</sub> and 37 °C. Calu-3 monolayers were polarized and cultured as described (<xref ref-type="bibr" rid="R30">Schloer et al., 2020b</xref>). Itraconazole (2 mg/mL, Sigma), fluoxetine (5 mM, Sigma) and remdesivir (10 mM, Hycultec) were solubilized in DMSO. The SARS-CoV-2 isolate hCoV-19/Germany/FI1103201/2020 (EPI-ISL_463008, mutation D614G in spike protein) was amplified on Vero E6 cells and used for the infection assays.</p>
</sec>
<sec id="S4">
<label>2.2</label>
<title>Cytotoxicity assay</title>
<p id="P6">Calu-3 cells were cultured at the indicated concentrations with either the solvent DMSO, itraconazole or with the combinations of itraconazole/ remdesivir (ItraRem) or fluoxetine/ remdesivir (FluoRem) for 48 h. Staurosporine solution (1 μM) served as a positive control for cytotoxic effects. After 48 hours of treatment, cell viability was evaluated by adding MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Sigma) to the cells for 4 h and OD<sub>562</sub> measurements according to the manufacturer’s protocols (Sigma).</p>
</sec>
<sec id="S5">
<label>2.3</label>
<title>Inoculation of cells and drug treatment</title>
<p id="P7">For infection, polarized Calu-3 and Vero cells were washed with PBS and inoculated at a multiplicity of infection (MOI) of 0.1 (Calu-3) or 0.01 (Vero E6) of virus diluted in infection-PBS (containing 0.2% BSA, 1% CaCl<sub>2</sub>, 1% MgCl<sub>2</sub>, 100 U/mL penicillin and 0.1 mg/mL streptomycin) at 37°C for 1 hours. Subsequently, cells were washed with PBS and further cultured in infection-DMEM (serum-free DMEM containing 0.2% BSA, 1 mM MgCl<sub>2</sub>, 0.9 mM CaCl<sub>2</sub>, 100 U/mL penicillin, and 0.1 mg/mL streptomycin) at 5% CO<sub>2</sub> and 37 °C. Cells were treated with the indicated remdesivir, itraconazole or fluoxetine concentration 2 hours post-infection (hpi) for the entire 48 hours infection period. After 48 hpi, apical culture supernatants were collected and immediately frozen at -80 °C until titration via plaque assay.</p>
</sec>
<sec id="S6">
<label>2.4</label>
<title>Plaque assay</title>
<p id="P8">To determine the number of infectious particles in the supernatant of treated cells, a standard plaque assay was performed. Briefly, Vero E6 cells grown to a monolayer in six-well dishes were washed with PBS and infected with serial dilutions of the respective supernatants in infection-PBS for 1 hour at 37 °C. The inoculum was replaced with 2x MEM (MEM containing 0.2% BSA, 2 mM L-glutamine 1 M HEPES, pH 7.2, 7.5% NaHCO<sub>3</sub>, 100 U/mL penicillin, 0.1 mg/mL streptomycin, and 0.4% Oxoid agar) and incubated at 37°C. Virus plaques were visualized by staining with neutral red, and virus titers were calculated as plaque-forming units (PFU) per mL.</p>
</sec>
<sec id="S7">
<label>2.5</label>
<title>Data and statistical analysis</title>
<p id="P9">A priori power analysis using G*Power 3.1 (<xref ref-type="bibr" rid="R7">Faul et al., 2007</xref>)) was performed to determine the sample sizes required to detect &gt; 90% reduction in virus titers at powers &gt; 0.8. Data were analyzed using the software GraphPad Prism version 8.00 (GraphPad). No outliers were detected.</p>
<p id="P10">Infectious viral titers are presented as means ± SEM of five measurements per experiment per condition. For dose-response curves, drug concentrations were log-transformed and virus titers were expressed as percentages of the mean virus titer in control cells (treated with the solvent DMSO) and data were analyzed by curve fitting using a 4 parameter logistic model. Drug combinatory effects were analyzed by using SynergyFinder, an open-source free stand-alone web application for the analysis of drug combination data (<xref ref-type="bibr" rid="R13">Ianevski et al., 2017</xref>). Synergy was evaluated based on the Zero Interaction Potency (ZIP), Bliss independence, and Highest single agent (HSA) reference models (<xref ref-type="bibr" rid="R11">He et al., 2018</xref>). We further analyzed the overall drug combination sensitivity score (CSS) by using the CSS method (<xref ref-type="bibr" rid="R21">Malyutina et al., 2019</xref>).</p>
</sec>
</sec>
<sec id="S8" sec-type="results">
<label>3</label>
<title>Results</title>
<sec id="S9">
<label>3.1</label>
<title>The clinically licensed antifungal drug itraconazole efficiently blocks the production of SARS-CoV-2 infectious particles</title>
<p id="P11">Based on the successful use of repurposing itraconazole for the treatment of influenza virus infection reported in our earlier studies (<xref ref-type="bibr" rid="R29">Schloer et al., 2019</xref>, <xref ref-type="bibr" rid="R30">2020b</xref>), we first established whether this clinically licensed drug also had an antiviral potential on the production of infectious SARS-CoV-2 particles. In line with our previous results (<xref ref-type="bibr" rid="R28">Schloer et al., 2020a</xref>), both Calu-3 and Vero E6 cell lines supported SARS-CoV-2 replication and produced high virus titers (<xref ref-type="fig" rid="F1">Fig. 1</xref>). Inoculation with the clinical isolate hCoV-19/Germany/FI1103201/2020 at MOI 0.1 yielded 1.46×10<sup>6</sup> PFU in Calu-3 cells and 6.37×10<sup>6</sup> PFU at MOI 0.01 in Vero cells at 48 hpi. Treatment with itraconazole 2 hpi potently inhibited SARS-CoV-2 replication in a dose-dependent manner in both cell types (<xref ref-type="fig" rid="F1">Fig. 1a</xref>). Fitting the experimental dose-response values to a nonlinear 4 parameter logistic model revealed half-maximal inhibitory (EC<sub>50</sub>) and 90% inhibitory concentrations (EC<sub>90</sub>) of 0.43 μM and 2.46 μM in Calu-3 cells, and even lower 50% and 90% inhibitory concentrations (0.39 μM and 0.87 μM) were determined for itraconazole antiviral activity in SARS-CoV-2 infected Vero cells (<xref ref-type="fig" rid="F1">Fig. 1b</xref>). Of note, no detectable cytotoxicity was observed with these doses (<xref ref-type="supplementary-material" rid="SD1">Fig. S1a</xref>). The itraconazole cytotoxic concentration required to reduce cell viability by 50% (CC50) was determined at 25.56 μM, resulting in a selectivity index (SI, defined as the ratio of CC<sub>50</sub> to EC<sub>50</sub>) of 25.56 μM which indicated an effective and safe antiviral window.</p>
</sec>
<sec id="S10">
<label>3.2</label>
<title>Remdesivir inhibits SARS-CoV-2 replication in polarized Calu-3 cells</title>
<p id="P12">We addressed the question of whether a host-targeting drug could be used in combination with a virus-directed drug for more efficient suppression of SARS-CoV-2 replication. Thus, we first assessed the antiviral capacity of remdesivir, a nucleotide analog prodrug that inhibits SARS-CoV-2 viral RNA-dependent RNA polymerase (<xref ref-type="bibr" rid="R9">Gordon et al., 2020</xref>). The EC<sub>50</sub> concentration was reached at 0.42 μM and EC<sub>90</sub> at 1.08 μM in Calu-3 cells (<xref ref-type="supplementary-material" rid="SD1">Fig. S2</xref>), well in line with published data (<xref ref-type="bibr" rid="R25">Pruijssers et al., 2020</xref>). Next, we determined viral replication in cells that had been treated with combinatory therapy. Because we recently published the potential use of repurposing the antidepressant fluoxetine for treatment of SARS-CoV-2 infection (<xref ref-type="bibr" rid="R28">Schloer et al., 2020a</xref>), we also assessed the effects of a combined fluoxetine/remdesivir (FluoRem) treatment in addition to the itraconazole/remdesivir (ItraRem) combination (<xref ref-type="fig" rid="F2">Fig. 2</xref>). Both drugs are clinically licensed and do not induce significant cytotoxicity over the whole concentration range ((<xref ref-type="bibr" rid="R28">Schloer et al., 2020a</xref>), and <xref ref-type="supplementary-material" rid="SD1">Fig. S1a</xref>). The combination treatments were also well-tolerated, and no cytotoxic effects were seen when cells were simultaneously treated with the drug pairs (<xref ref-type="supplementary-material" rid="SD1">Fig. S1b, c</xref>).</p>
</sec>
<sec id="S11">
<label>3.3</label>
<title>Combinatory treatments with the drug pairs itraconazole-remdesivir or fluoxetine-remdesivir show enhanced antiviral activity due to synergistic interaction</title>
<p id="P13">For all drugs, we chose those concentrations that were not sufficient to achieve a 90% reduction when individually applied (<xref ref-type="fig" rid="F3">Fig 3a</xref>). For both ItraRem and FluoRem combinations, a potent reduction in virus titers was detected in all cases. Of note, several combinations yielded a reduction &gt; 90% of the maximum virus titers produced in control cells (<xref ref-type="fig" rid="F3">Fig. 3b</xref>).</p>
<p id="P14">We, next considered the pharmacological interactions of the respective drug pairs. Thus, we evaluated the drug interactions via Bliss independence, Highest single agent (HSA), and ZIP, three commonly used reference synergy models that differ in their basic assumptions of drug interaction they are based on. The results, presented in <xref ref-type="fig" rid="F4">Figs. 4</xref> and <xref ref-type="fig" rid="F5">5</xref>, consistently argued for synergistic action of remdesivir with itraconazole and fluoxetine, as indicated by the positive average synergy score across all models. Closer inspection of the drug interaction relationships and landscape visualizations revealed that for ItraRem, the highest synergy scores were calculated with the lower concentration ranges of both drugs (<xref ref-type="fig" rid="F4">Fig. 4</xref>). The strong synergy led to an overall drug combination sensitivity score (CSS) of 89.64, resulting in &gt;90% inhibition already at 500 nM of remdesivir and 250 nM of itraconazole. FluoRem combination treatment had a higher average synergy score, as well as a higher CSS score than ItraRem (92.82 vs 89.64), suggesting that this drug combination is more likely to show synergy. Importantly, for all models, the FluoRem combinations that met the ≥ 90% inhibition criterion were well within the high synergy area (<xref ref-type="fig" rid="F5">Fig. 5</xref>).</p>
</sec>
</sec>
<sec id="S12" sec-type="discussion">
<label>4</label>
<title>Discussion</title>
<p id="P15">The nucleoside analog remdesivir with broad-spectrum antiviral activity against a range of viruses including Ebola, Marburg, MERS, and SARS inhibits viral RNA polymerase and is also active against SARS-CoV-2 (<xref ref-type="bibr" rid="R38">Warren et al., 2016</xref>; <xref ref-type="bibr" rid="R32">Sheahan et al., 2017</xref>, <xref ref-type="bibr" rid="R33">2020</xref>; <xref ref-type="bibr" rid="R1">Agostini et al., 2018</xref>; <xref ref-type="bibr" rid="R5">Brown et al., 2019</xref>). Indeed, remedesivir was the first new drug to receive an FDA emergency use authorization for the treatment of severe COVID-19 cases. However, a common concern about virus-directed antivirals is the development of drug resistance. Due to their error-prone replication mode, drug-resistant viruses are increasingly encountered (<xref ref-type="bibr" rid="R35">Strasfeld and Chou, 2010</xref>), as observed with the influenza neuraminidase inhibitor oseltamivir (<xref ref-type="bibr" rid="R15">Kim et al., 2013</xref>). Because profound changes would be required to allow viruses to replicate independently of otherwise essential host factors, the development of host-directed therapeutics is an emerging concept. However, host-directed drugs will rather cause impaired viral replication than complete eradication, thus demanding high drug concentrations and starting treatment start as early as possible and for extended durations, which is often associated with poor patient compliance. Because of these shortcomings, combinatory treatments with both virus- and host-directed drugs are explored for enhanced treatment success.</p>
<p id="P16">Enveloped viruses such as SARS-CoV-2 depend on the fusion of their lipid hull with the host membrane to get access to the cytosol. The SARS-CoV-2 spike protein, which protrudes from the virus surface, mediates initial binding to angiotensin-converting enzyme 2 (ACE2), which serves as the host cell surface receptor (<xref ref-type="bibr" rid="R20">Li et al., 2003</xref>; <xref ref-type="bibr" rid="R18">Lan et al., 2020</xref>; <xref ref-type="bibr" rid="R24">Ou et al., 2020</xref>; Zh<xref ref-type="bibr" rid="R24">ou et al., 2020</xref>). To promote fusion with the host cell membrane, the spike protein needs to be primed by proteolytic cleavage, which can be mediated by several host proteases. Transmembrane protease serine 2 (TMPRSS2)-mediated cleavage leads to fusion with the plasma membrane, while endosome-residing proteases are utilized by endocytosed SARS-CoV-2 particles for fusion within endosomes. Since both routes have been reported to contribute to the SARS-CoV-2 infectivity (<xref ref-type="bibr" rid="R12">Hoffmann et al., 2020</xref>), the endosomal compartment is also a critical host/pathogen interface for SARS-CoV-2. Our previous studies strongly support the late endosomal cholesterol balance as a cellular target for antiviral intervention (<xref ref-type="bibr" rid="R22">Musiol et al., 2013</xref>; <xref ref-type="bibr" rid="R17">Kühnl et al., 2018</xref>; <xref ref-type="bibr" rid="R29">Schloer et al., 2019</xref>, <xref ref-type="bibr" rid="R28">2020a</xref>, <xref ref-type="bibr" rid="R30">2020b</xref>). Notably, endolysosomal lipid storage and cholesterol build-up could be induced via repurposing of drugs approved for unrelated applications. We found that the triazole derivative itraconazole, a clinically licensed antifungal drug (<xref ref-type="bibr" rid="R23">Organization, 2019</xref>) that directly inhibits the endosomal cholesterol transporter NPC1 (<xref ref-type="bibr" rid="R37">Trinh et al., 2017</xref>) has an antiviral potential on the endosomal fusion of enveloped viruses including influenza viruses (<xref ref-type="bibr" rid="R29">Schloer et al., 2019</xref>). The findings presented in this study add SARS-CoV-2 to the spectrum of itraconazole-sensitive enveloped viruses. Our results reveal a potent antiviral activity of itraconazole on the production of SARS-CoV-2 infectious particles, with EC50 values comparable to what we previously reported for itraconazole-mediated antiviral activity against IAV subtypes. The bioavailability after oral application of itraconazole is low because of the low water solubility of this compound (<xref ref-type="bibr" rid="R10">Grant Prentice and Glasmacher, 2005</xref>; <xref ref-type="bibr" rid="R6">Domínguez-Gil Hurlé et al., 2006</xref>). Only limited amounts are absorbed from the gastrointestinal tract after ionization, and levels depend on the individual gastric acidity (<xref ref-type="bibr" rid="R34">Shin et al., 2004</xref>; <xref ref-type="bibr" rid="R6">Domínguez-Gil Hurlé et al., 2006</xref>; <xref ref-type="bibr" rid="R3">Bae et al., 2011</xref>; <xref ref-type="bibr" rid="R19">Lestner and Hope, 2013</xref>; <xref ref-type="bibr" rid="R2">Allegra et al., 2017</xref>). However, our previous study revealed a beneficial antiviral activity in vivo (<xref ref-type="bibr" rid="R29">Schloer et al., 2019</xref>).</p>
<p id="P17">We recently discovered that the widely used antidepressant fluoxetine has strong SARS-CoV-2 antiviral activity (<xref ref-type="bibr" rid="R28">Schloer et al., 2020a</xref>). Together with the findings presented here on the inhibitory function of itraconazole treatment on SARS-CoV-2 replication, these results suggest that both drugs are promising candidates for repurposing as a host-directed drug for SARS-CoV-2 infection treatment. Both drugs most likely interfere with the proper endosomal cholesterol levels. Whereas itraconazole und posaconazole both directly inhibit the endosomal cholesterol transporter NPC1 (<xref ref-type="bibr" rid="R37">Trinh et al., 2017</xref>), fluoxetine functionally blocks the endolysosome-residing enzyme sphingomyelin phosphodiesterase (“acid sphingomyelinase”, ASM), which in turn causes sphingomyelin accumulation and negatively affects cholesterol release from this compartment (<xref ref-type="bibr" rid="R16">Kornhuber et al., 2010</xref>).</p>
</sec>
<sec id="S13" sec-type="conclusions">
<label>6</label>
<title>Conclusion</title>
<p id="P18">While remdesivir and the host-directed drugs itraconazole or fluoxetine target independent pathways, we found that drug combinations together with remdesivir (ItraRem and FluoRem) showed stronger antiviral activities against SARS-CoV-2 than the remdesivir monotherapy. Moreover, the overall therapeutic effect of the combinations was larger than the expected sum of the independent drug effects. Our analysis on the antiviral activity of combinatory drug combinations via commonly used interaction models argue for an enhanced efficacy that is based on synergistic drug interaction and suggests promising novel options for SARS-CoV-2 treatment.</p>
</sec>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>Supporting Information</label>
<media xlink:href="EMS98622-supplement-Supporting_Information.pdf" mimetype="application" mime-subtype="pdf" id="N66325" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<ack id="S14">
<title>Acknowledgements</title>
<p>We thank Jonathan Hentrey for help with the plaque assays.</p>
<sec id="S15">
<title>Funding</title>
<p>This research was funded by grants from the German Research Foundation (DFG), CRC1009 “Breaking Barriers”, Project A06 (to U.R.) and B02 (to S.L.), CRC 1348 “Dynamic Cellular Interfaces”, Project A11 (to U.R.), DFG Lu477/23-1 (to S.L.), the European Research Council No. 716063 (to SZ and JT), the Academy of Finland No. 317680 (to SZ and JT), the Interdisciplinary Center for Clinical Research (IZKF) of the Münster Medical School, grant number Re2/022/20 (to U.R.) and from the Innovative Medizinische Forschung (IMF) of the Münster Medical School, grant number SC121912 (to S.S.). S.S., S.L., and U.R. are members of the German FluResearchNet, a nationwide research network on zoonotic influenza.</p>
</sec>
</ack>
<fn-group>
<fn id="FN1" fn-type="conflict">
<p id="P19">
<bold>Conflict of Interest</bold>
</p>
<p id="P20">The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</p>
</fn>
<fn id="FN2" fn-type="con">
<p id="P21">
<bold>Author Contributions</bold>
</p>
<p id="P22">Conceptualization and methodology, S.S., U.R.; validation, formal analysis, investigation, data curation, S.S., J.T., U.R.; resources, J.T., S.L.; U.R.; writing—original draft preparation, U.R.; writing—review and editing, S.S., S.L., U.R.; visualization, S.S.; supervision, U.R., S.L., project administration, U.R.; funding acquisition, U.R. All authors have read and agreed to the published version of the manuscript.</p>
</fn>
</fn-group>
<ref-list>
<ref id="R1">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agostini</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Andres</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Sims</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Sheahan</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>X</given-names>
</name>
<etal/>
</person-group>
<article-title>Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease</article-title>
<source>MBio</source>
<year>2018</year>
<volume>9</volume>
<fpage>2020</fpage>
</element-citation>
</ref>
<ref id="R2">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Allegra</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fatiguso</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Francia De</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Favata</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Pirro</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Carcieri</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>
<article-title>Evaluation of posaconazole pharmacokinetics in adult patients with invasive fungal infection</article-title>
<source>Biomedicines</source>
<year>2017</year>
<volume>5</volume>
</element-citation>
</ref>
<ref id="R3">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bae</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Shim</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Mun</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>EY</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>JG</given-names>
</name>
<etal/>
</person-group>
<article-title>Increased Oral Bioavailability of Itraconazole and Its Active Metabolite, 7-Hydroxyitraconazole, When Coadministered With a Vitamin C Beverage in Healthy Participants</article-title>
<source>J Clin Pharmacol</source>
<year>2011</year>
<volume>51</volume>
<fpage>444</fpage>
<lpage>451</lpage>
</element-citation>
</ref>
<ref id="R4">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baud</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Nielsen-Saines</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Musso</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pomar</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Favre</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Real estimates of mortality following COVID-19 infection</article-title>
<source>Lancet Infect Dis</source>
<year>2011</year>
<volume>20</volume>
<fpage>773</fpage>
</element-citation>
</ref>
<ref id="R5">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Won</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Dinnon</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Sims</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>JY</given-names>
</name>
<etal/>
</person-group>
<article-title>Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase</article-title>
<source>Antiviral Res</source>
<year>2019</year>
<volume>169</volume>
</element-citation>
</ref>
<ref id="R6">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Domínguez-Gil Hurlé</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sánchez Navarro</surname>
<given-names>A</given-names>
</name>
<name>
<surname>García Sánchez</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Therapeutic drug monitoring of itraconazole and the relevance of pharmacokinetic interactions</article-title>
<source>Clin Microbiol Infect</source>
<year>2006</year>
<volume>12</volume>
<fpage>97</fpage>
<lpage>106</lpage>
</element-citation>
</ref>
<ref id="R7">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Faul</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Erdfelder</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Buchner</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences</article-title>
<source>Behav Res Methods</source>
<year>2007</year>
<volume>39</volume>
<fpage>175</fpage>
<lpage>191</lpage>
</element-citation>
</ref>
<ref id="R8">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fierabracci</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Arena</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>COVID-19: A review on diagnosis, treatment, and prophylaxis</article-title>
<source>Int J Mol Sci</source>
<year>2020</year>
<volume>21</volume>
<fpage>1</fpage>
<lpage>16</lpage>
</element-citation>
</ref>
<ref id="R9">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gordon</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Tchesnokov</surname>
<given-names>EP</given-names>
</name>
<name>
<surname>Woolner</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>DP</given-names>
</name>
<etal/>
</person-group>
<article-title>Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency</article-title>
<source>J Biol Chem</source>
<year>2020</year>
<volume>295</volume>
<fpage>6785</fpage>
<lpage>6797</lpage>
</element-citation>
</ref>
<ref id="R10">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grant Prentice</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Glasmacher</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Making sense of itraconazole pharmacokinetics</article-title>
<source>J Antimicrob Chemother</source>
<year>2005</year>
<volume>56</volume>
<fpage>17</fpage>
<lpage>22</lpage>
</element-citation>
</ref>
<ref id="R11">
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kulesskiy</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Saarela</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Turunen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wennerberg</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Aittokallio</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>
<chapter-title>Methods for high-throughput drug combination screening and synergy scoring</chapter-title>
<source>Methods in Molecular Biology</source>
<publisher-name>Humana Press Inc</publisher-name>
<year>2018</year>
<fpage>351</fpage>
<lpage>398</lpage>
</element-citation>
</ref>
<ref id="R12">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoffmann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kleine-Weber</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Schroeder</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Krüger</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Herrler</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Erichsen</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor</article-title>
<source>Cell</source>
<year>2020</year>
<volume>181</volume>
<fpage>271</fpage>
<lpage>280</lpage>
<comment>e8</comment>
</element-citation>
</ref>
<ref id="R13">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ianevski</surname>
<given-names>A</given-names>
</name>
<name>
<surname>He</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Aittokallio</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>SynergyFinder: A web application for analyzing drug combination dose-response matrix data</article-title>
<source>Bioinformatics</source>
<year>2017</year>
<volume>33</volume>
<fpage>2413</fpage>
<lpage>2415</lpage>
</element-citation>
</ref>
<ref id="R14">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ianevski</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fenstad</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Biza</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zusinaite</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Reisberg</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>
<article-title>Potential antiviral options against SARS-CoV-2 infection</article-title>
<source>Viruses</source>
<year>2020</year>
<volume>12</volume>
</element-citation>
</ref>
<ref id="R15">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Resende</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wennekes</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Bance</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Buchini</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Mechanism-based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activity</article-title>
<source>Science (80-)</source>
<year>2013</year>
<volume>340</volume>
<fpage>71</fpage>
<lpage>75</lpage>
</element-citation>
</ref>
<ref id="R16">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kornhuber</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tripal</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Reichel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mühle</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rhein</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Muehlbacher</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<source>Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): A Novel Pharmacological Group of Drugs with Broad Clinical Applications</source>
<year>2010</year>
</element-citation>
</ref>
<ref id="R17">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kühnl</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Musiol</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Heitzig</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Ehrhardt</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Grewal</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>
<article-title>Late endosomal/lysosomal cholesterol accumulation is a host cell-protective mechanism inhibiting endosomal release of influenza A virus</article-title>
<source>MBio</source>
<year>2018</year>
<volume>9</volume>
<fpage>e01345</fpage>
<lpage>18</lpage>
</element-citation>
</ref>
<ref id="R18">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor</article-title>
<source>Nature</source>
<year>2020</year>
<volume>581</volume>
<fpage>215</fpage>
<lpage>220</lpage>
</element-citation>
</ref>
<ref id="R19">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lestner</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hope</surname>
<given-names>WW</given-names>
</name>
</person-group>
<article-title>Itraconazole: An update on pharmacology and clinical use for treatment of invasive and allergic fungal infections</article-title>
<source>Expert Opin Drug Metab Toxicol</source>
<year>2013</year>
<volume>9</volume>
<fpage>911</fpage>
<lpage>926</lpage>
</element-citation>
</ref>
<ref id="R20">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Vasllieva</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sui</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Berne</surname>
<given-names>MA</given-names>
</name>
<etal/>
</person-group>
<article-title>Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus</article-title>
<source>Nature</source>
<year>2003</year>
<volume>426</volume>
<fpage>450</fpage>
<lpage>454</lpage>
</element-citation>
</ref>
<ref id="R21">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malyutina</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Majumder</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Pessia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Heckman</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer</article-title>
<source>PLoS Comput Biol</source>
<year>2019</year>
<volume>15</volume>
</element-citation>
</ref>
<ref id="R22">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Musiol</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gran</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ehrhardt</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ludwig</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Grewal</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Gerke</surname>
<given-names>V</given-names>
</name>
<etal/>
</person-group>
<article-title>Annexin A6-balanced late endosomal cholesterol controls influenza a replication and propagation</article-title>
<source>MBio</source>
<year>2013</year>
<volume>4</volume>
<fpage>1</fpage>
<lpage>11</lpage>
</element-citation>
</ref>
<ref id="R23">
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Organization</surname>
<given-names>WH</given-names>
</name>
</person-group>
<source>World Health Organization Model List of Essential Medicines</source>
<publisher-loc>Geneve</publisher-loc>
<year>2019</year>
</element-citation>
</ref>
<ref id="R24">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ou</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mi</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV</article-title>
<source>Nat Commun</source>
<year>2020</year>
<volume>11</volume>
<fpage>1</fpage>
<lpage>12</lpage>
</element-citation>
</ref>
<ref id="R25">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pruijssers</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>George</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Schäfer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Leist</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Gralinksi</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Dinnon</surname>
<given-names>KH</given-names>
</name>
<etal/>
</person-group>
<article-title>Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice</article-title>
<source>Cell Rep</source>
<year>2020</year>
<volume>32</volume>
<fpage>107940</fpage>
</element-citation>
</ref>
<ref id="R26">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pushpakom</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Iorio</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Eyers</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Escott</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Hopper</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wells</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Drug repurposing: Progress, challenges and recommendations</article-title>
<source>Nat Rev Drug Discov</source>
<year>2018</year>
<volume>18</volume>
<fpage>41</fpage>
<lpage>58</lpage>
</element-citation>
</ref>
<ref id="R27">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rajgor</surname>
<given-names>DD</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Archuleta</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bagdasarian</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Quek</surname>
<given-names>SC</given-names>
</name>
</person-group>
<article-title>The many estimates of the COVID-19 case fatality rate</article-title>
<source>Lancet Infect Dis</source>
<year>2020</year>
<volume>20</volume>
<fpage>776</fpage>
<lpage>777</lpage>
</element-citation>
</ref>
<ref id="R28">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schloer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Brunotte</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Goretzko</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mecate-Zambrano</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Korthals</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Gerke</surname>
<given-names>V</given-names>
</name>
<etal/>
</person-group>
<article-title>Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine</article-title>
<source>Emerg Microbes Infect</source>
<year>2020a</year>
<fpage>1</fpage>
<lpage>26</lpage>
</element-citation>
</ref>
<ref id="R29">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schloer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Goretzko</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kühnl</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brunotte</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ludwig</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rescher</surname>
<given-names>U</given-names>
</name>
</person-group>
<article-title>The clinically licensed antifungal drug itraconazole inhibits influenza virus <italic>in vitro</italic> and <italic>in vivo</italic>
</article-title>
<source>Emerg Microbes Infect</source>
<year>2018</year>
<volume>8</volume>
<fpage>80</fpage>
<lpage>93</lpage>
</element-citation>
</ref>
<ref id="R30">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schloer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Goretzko</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pleschka</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ludwig</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rescher</surname>
<given-names>U</given-names>
</name>
</person-group>
<article-title>Combinatory Treatment with Oseltamivir and Itraconazole Targeting Both Virus and Host Factors in Influenza A Virus Infection</article-title>
<source>Viruses</source>
<year>2020b</year>
<volume>12</volume>
<fpage>703</fpage>
</element-citation>
</ref>
<ref id="R31">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwegmann</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brombacher</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Host-directed drug targeting of factors hijacked by pathogens</article-title>
<source>Sci Signal</source>
<year>2008</year>
<volume>1</volume>
<fpage>re8</fpage>
</element-citation>
</ref>
<ref id="R32">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheahan</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Sims</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Menachery</surname>
<given-names>VD</given-names>
</name>
<name>
<surname>Gralinski</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Case</surname>
<given-names>JB</given-names>
</name>
<etal/>
</person-group>
<article-title>Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses</article-title>
<source>Sci Transl Med</source>
<year>2017</year>
<fpage>9</fpage>
</element-citation>
</ref>
<ref id="R33">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheahan</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Sims</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Leist</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Schäfer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Won</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>AJ</given-names>
</name>
<etal/>
</person-group>
<article-title>Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV</article-title>
<source>Nat Commun</source>
<year>2020</year>
<volume>11</volume>
<fpage>1</fpage>
<lpage>14</lpage>
</element-citation>
</ref>
<ref id="R34">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shin</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>KY</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>MG</given-names>
</name>
</person-group>
<article-title>Dose-Dependent Pharmacokinetics of Itraconazole after Intravenous or Oral Administration to Rats: Intestinal First-Pass Effect</article-title>
<source>Antimicrob Agents Chemother</source>
<year>2004</year>
<volume>48</volume>
<fpage>1756</fpage>
<lpage>1762</lpage>
</element-citation>
</ref>
<ref id="R35">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strasfeld</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Chou</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Antiviral drug resistance: Mechanisms and clinical implications</article-title>
<source>Infect Dis Clin North Am</source>
<year>2010</year>
<volume>24</volume>
<fpage>809</fpage>
<lpage>833</lpage>
</element-citation>
</ref>
<ref id="R36">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bidon</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jaimes</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Whittaker</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Daniel</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Coronavirus membrane fusion mechanism offers a potential target for antiviral development</article-title>
<source>Antiviral Res</source>
<year>2020</year>
<volume>178</volume>
</element-citation>
</ref>
<ref id="R37">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trinh</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>De Brabander</surname>
<given-names>JK</given-names>
</name>
<etal/>
</person-group>
<article-title>Triazoles inhibit cholesterol export from lysosomes by binding to NPC1</article-title>
<source>Proc Natl Acad Sci</source>
<year>2017</year>
<volume>114</volume>
<fpage>89</fpage>
<lpage>94</lpage>
</element-citation>
</ref>
<ref id="R38">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warren</surname>
<given-names>TK</given-names>
</name>
<name>
<surname>Jordan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lo</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Ray</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Mackman</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Soloveva</surname>
<given-names>V</given-names>
</name>
<etal/>
</person-group>
<article-title>Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys</article-title>
<source>Nature</source>
<year>2016</year>
<volume>531</volume>
<fpage>381</fpage>
<lpage>385</lpage>
</element-citation>
</ref>
<ref id="R39">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bushman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kishore</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Niehus</surname>
<given-names>R</given-names>
</name>
<name>
<surname>de Salazar</surname>
<given-names>PM</given-names>
</name>
<etal/>
</person-group>
<article-title>Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan</article-title>
<source>China Nat Med</source>
<year>2020</year>
<volume>26</volume>
<fpage>506</fpage>
<lpage>510</lpage>
</element-citation>
</ref>
<ref id="R40">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Yang Lou</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>XG</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group>
<article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title>
<source>Nature</source>
<year>2020</year>
<volume>579</volume>
<fpage>270</fpage>
<lpage>273</lpage>
</element-citation>
</ref>
<ref id="R41">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zumla</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hui</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Azhar</surname>
<given-names>EI</given-names>
</name>
<name>
<surname>Memish</surname>
<given-names>ZA</given-names>
</name>
<name>
<surname>Maeurer</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Reducing mortality from 2019-nCoV: host-directed therapies should be an option</article-title>
<source>Lancet</source>
<year>2020</year>
<volume>395</volume>
<fpage>e35</fpage>
<lpage>e36</lpage>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>Analysis of itraconazole-mediated reduction of SARS-CoV-2 replication. Calu-3 and Vero E6 cells were infected with 0.1 MOI of SARS-CoV-2. At 2 hpi, cells were treated with itraconazole at the indicated concentrations. (a) Mean infectious viral titers ± SEM, (b) Mean percent inhibition ± SEM of SARS-CoV-2 replication, with mean virus titer in control cells (treated with the solvent DMSO) set to 100%; n = 5. LogEC<sub>50</sub> and LogEC<sub>90</sub> values were determined by fitting a non-linear regression model. (Calu-3: EC<sub>50</sub> = 0.43 μM, EC<sub>90</sub> = 2.46 μM; Vero E6: EC<sub>50</sub> = 0.39 μM, EC<sub>90</sub> = 0.87 μM).</p>
</caption>
<graphic xlink:href="EMS98622-f001"/>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>Antiviral activities of treatments. Infectious virus production in Calu-3 cells treated as indicated 2 hpi. Each symbol represents plaque-forming units (PFU) per mL detected in a single experimental sample, lines indicate means.</p>
</caption>
<graphic xlink:href="EMS98622-f002"/>
</fig>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<p>Antiviral activities of single and combination treatments. Calu-3 cells were treated with the indicated drug combinations for 48 h. (a) Single treatment, (b) combinatory treatment. Bars represent mean percent inhibition ± SEM of infectious virus production, with mean virus titer produced in control cells (treated with the solvent DMSO) set to 100%; n = 5. Dotted line, 90% reduction in viral titer.</p>
</caption>
<graphic xlink:href="EMS98622-f003"/>
</fig>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<p>Evaluation of the pharmacological interactions of itraconazole and remdesivir (ItraRem). ZIP, Bliss independence, and Highest single agent (HSA) reference models were used to assess the interaction landscapes. Interaction surfaces are color-coded according to the synergy scores of the responses.</p>
</caption>
<graphic xlink:href="EMS98622-f004"/>
</fig>
<fig id="F5" position="float">
<label>Figure 5</label>
<caption>
<p>Evaluation of the pharmacological interactions of fluoxetine and remdesivir (FluoRem). ZIP, Bliss independence, and Highest single agent (HSA) reference models were used to assess the interaction landscapes. Interaction surfaces are color-coded according to the synergy scores of the responses.</p>
</caption>
<graphic xlink:href="EMS98622-f005"/>
</fig>
</floats-group>
</article>
